164 related articles for article (PubMed ID: 35892885)
21. Clinical outcomes and toxicity of proton beam therapy for advanced cholangiocarcinoma.
Makita C; Nakamura T; Takada A; Takayama K; Suzuki M; Ishikawa Y; Azami Y; Kato T; Tsukiyama I; Kikuchi Y; Hareyama M; Murakami M; Fuwa N; Hata M; Inoue T
Radiat Oncol; 2014 Jan; 9():26. PubMed ID: 24422711
[TBL] [Abstract][Full Text] [Related]
22. Proton beam radiotherapy for patients with early-stage and advanced lung cancer: a narrative review with contemporary clinical recommendations.
Chiang JS; Yu NY; Daniels TB; Liu W; Schild SE; Sio TT
J Thorac Dis; 2021 Feb; 13(2):1270-1285. PubMed ID: 33717598
[TBL] [Abstract][Full Text] [Related]
23. Proton beam therapy versus stereotactic body radiotherapy for hepatocellular carcinoma: practice patterns, outcomes, and the effect of biologically effective dose escalation.
Hasan S; Abel S; Verma V; Webster P; Arscott WT; Wegner RE; Kirichenko A; Simone CB
J Gastrointest Oncol; 2019 Oct; 10(5):999-1009. PubMed ID: 31602338
[TBL] [Abstract][Full Text] [Related]
24. A collaborative analysis of stereotactic lung radiotherapy outcomes for early-stage non-small-cell lung cancer using daily online cone-beam computed tomography image-guided radiotherapy.
Grills IS; Hope AJ; Guckenberger M; Kestin LL; Werner-Wasik M; Yan D; Sonke JJ; Bissonnette JP; Wilbert J; Xiao Y; Belderbos J
J Thorac Oncol; 2012 Sep; 7(9):1382-93. PubMed ID: 22843086
[TBL] [Abstract][Full Text] [Related]
25. Long-term Outcomes After Moderate Hypofractionated Proton Therapy for Centrally Located Non-small Cell Lung Cancer.
Nakamura M; Ishikawa H; Ohnishi K; Baba K; Sumiya T; Murakami M; Hiroshima Y; Mizumoto M; Okumura T; Sakurai H
Anticancer Res; 2023 May; 43(5):2003-2013. PubMed ID: 37097674
[TBL] [Abstract][Full Text] [Related]
26. Stereotactic body radiation therapy with higher biologically effective dose is associated with improved survival in stage II non-small cell lung cancer.
Yan SX; Qureshi MM; Dyer M; Truong MT; Mak KS
Lung Cancer; 2019 May; 131():147-153. PubMed ID: 31027693
[TBL] [Abstract][Full Text] [Related]
27. Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer.
Chang JY; Zhang X; Wang X; Kang Y; Riley B; Bilton S; Mohan R; Komaki R; Cox JD
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1087-96. PubMed ID: 16682145
[TBL] [Abstract][Full Text] [Related]
28. Clinical Effectiveness of Hypofractionated Proton Beam Therapy for Liver Metastasis From Breast Cancer.
Kim TH; Lee KS; Sim SH; Kim YJ; Kim DY; Chae H; Lee EG; Han JH; Jung SY; Lee S; Kang HS; Lee ES
Front Oncol; 2021; 11():783327. PubMed ID: 34804986
[TBL] [Abstract][Full Text] [Related]
29. Association of lung and heart dose with survival in patients with non-small cell lung cancer underwent volumetric modulated arc therapy.
Shen L; Liu C; Jin J; Han C; Zhou Y; Zheng X; Gong C; Chen M; Xie C; Jin X
Cancer Manag Res; 2019; 11():6091-6098. PubMed ID: 31308747
[TBL] [Abstract][Full Text] [Related]
30. Proton beam stereotactic body radiotherapy and hypofractionated therapy with pencil beam scanning is safe and effective for advanced hepatocellular carcinoma and intrahepatic cholangiocarcinoma: A single center experience.
Yang AH; Urrunaga NH; Siddiqui O; Wu A; Schliep M; Mossahebi S; Shetty K; Regine WF; Molitoris JK; Lominadze Z
J Radiosurg SBRT; 2023; 9(1):43-52. PubMed ID: 38029012
[TBL] [Abstract][Full Text] [Related]
31. Hypofractionated proton beam therapy for centrally located lung cancer.
Nakamura N; Hotta K; Zenda S; Baba H; Kito S; Akita T; Motegi A; Hojo H; Nakamura M; Parshuram RV; Okumura M; Akimoto T
J Med Imaging Radiat Oncol; 2019 Aug; 63(4):552-556. PubMed ID: 31145553
[TBL] [Abstract][Full Text] [Related]
32. Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer.
Lin SH; Hobbs BP; Verma V; Tidwell RS; Smith GL; Lei X; Corsini EM; Mok I; Wei X; Yao L; Wang X; Komaki RU; Chang JY; Chun SG; Jeter MD; Swisher SG; Ajani JA; Blum-Murphy M; Vaporciyan AA; Mehran RJ; Koong AC; Gandhi SJ; Hofstetter WL; Hong TS; Delaney TF; Liao Z; Mohan R
J Clin Oncol; 2020 May; 38(14):1569-1579. PubMed ID: 32160096
[TBL] [Abstract][Full Text] [Related]
33. Clinical Outcomes in Patients with Recurrent Glioblastoma Treated with Proton Beam Therapy Reirradiation: Analysis of the Multi-Institutional Proton Collaborative Group Registry.
Saeed AM; Khairnar R; Sharma AM; Larson GL; Tsai HK; Wang CJ; Halasz LM; Chinnaiyan P; Vargas CE; Mishra MV
Adv Radiat Oncol; 2020; 5(5):978-983. PubMed ID: 33083661
[TBL] [Abstract][Full Text] [Related]
34. Comparison of dose-volume histograms between proton beam and X-ray conformal radiotherapy for locally advanced non-small-cell lung cancer.
Ohno T; Oshiro Y; Mizumoto M; Numajiri H; Ishikawa H; Okumura T; Terunuma T; Sakae T; Sakurai H
J Radiat Res; 2015 Jan; 56(1):128-33. PubMed ID: 25368341
[TBL] [Abstract][Full Text] [Related]
35. Assessing efficacy and safety of stereotactic body radiation therapy for oligometastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) wild type.
Hu X; Li H; Liu H; Liu Z; Xia T; Zhang J; Wang Y
Transl Cancer Res; 2021 Jan; 10(1):184-194. PubMed ID: 35116250
[TBL] [Abstract][Full Text] [Related]
36. Predicting 5-Year Progression and Survival Outcomes for Early Stage Non-small Cell Lung Cancer Treated with Stereotactic Ablative Radiation Therapy: Development and Validation of Robust Prognostic Nomograms.
Kang J; Ning MS; Feng H; Li H; Bahig H; Brooks ED; Welsh JW; Ye R; Miao H; Chang JY
Int J Radiat Oncol Biol Phys; 2020 Jan; 106(1):90-99. PubMed ID: 31586665
[TBL] [Abstract][Full Text] [Related]
37. Feasibility and efficacy of helical intensity-modulated radiotherapy for stage III non-small cell lung cancer in comparison with conventionally fractionated 3D-CRT.
He J; Huang Y; Chen Y; Shi S; Ye L; Hu Y; Zhang J; Zeng Z
J Thorac Dis; 2016 May; 8(5):862-71. PubMed ID: 27162660
[TBL] [Abstract][Full Text] [Related]
38. Comparative Outcomes After Definitive Chemoradiotherapy Using Proton Beam Therapy Versus Intensity Modulated Radiation Therapy for Esophageal Cancer: A Retrospective, Single-Institutional Analysis.
Xi M; Xu C; Liao Z; Chang JY; Gomez DR; Jeter M; Cox JD; Komaki R; Mehran R; Blum MA; Hofstetter WL; Maru DM; Bhutani MS; Lee JH; Weston B; Ajani JA; Lin SH
Int J Radiat Oncol Biol Phys; 2017 Nov; 99(3):667-676. PubMed ID: 29280461
[TBL] [Abstract][Full Text] [Related]
39. Overall Survival After Treatment of Localized Prostate Cancer With Proton Beam Therapy, External-Beam Photon Therapy, or Brachytherapy.
Liu Y; Patel SA; Jani AB; Gillespie TW; Patel PR; Godette KD; Hershatter BW; Shelton JW; McDonald MW
Clin Genitourin Cancer; 2021 Jun; 19(3):255-266.e7. PubMed ID: 32972877
[TBL] [Abstract][Full Text] [Related]
40. Pathologic complete response (pCR) rates and outcomes after neoadjuvant chemoradiotherapy with proton or photon radiation for adenocarcinomas of the esophagus and gastroesophageal junction.
DeCesaris CM; Berger M; Choi JI; Carr SR; Burrows WM; Regine WF; Simone CB; Molitoris JK
J Gastrointest Oncol; 2020 Aug; 11(4):663-673. PubMed ID: 32953150
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
